ARTICLE | Company News
Caliber Biotherapeutics, iBio deal
January 20, 2014 8:00 AM UTC
The partners designated a fusion protein for cancer as the first product target to advance under a 2013 deal granting Caliber a non-exclusive license to use iBio's iBioLaunch plant-based vaccine and t...